Figure 3 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms

Figure 3 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms

<p><b>A,</b> OPLS-DA plot showing separation of unwell patients with solid tumor diagnoses (blue, filled) from unwell patients with noncancer diagnoses (black, open). <b>B,</b> Sensitivity (dots), specificity (dashes), and F<sub>1</sub> score (continuous) fo...

保存先:

書誌詳細
第一著者:	James R. Larkin (14936324) (author)
その他の著者:	Susan Anthony (15039111) (author), Vanessa A. Johanssen (15039114) (author), Tianrong Yeo (15039117) (author), Megan Sealey (12045959) (author), Abi G. Yates (14029965) (author), Claire Friedemann Smith (15039120) (author), Timothy D.W. Claridge (15039123) (author), Brian D. Nicholson (2889917) (author), Julie-Ann Moreland (15039126) (author), Fergus Gleeson (4055239) (author), Nicola R. Sibson (14936336) (author), Daniel C. Anthony (15039129) (author), Fay Probert (849357) (author)
出版事項:	2025
主題:	Cancer Molecular and Cellular Biology Cancer Detection and Diagnosis Methods and Technology Biomarkers Diagnostic biomarkers Early detection biomarkers Liquid Biopsy Metabolism Metabolomics Tumor Staging
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Figure 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
著者:: James R. Larkin (14936324)
出版事項: (2025)

Figure 2 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
著者:: James R. Larkin (14936324)
出版事項: (2025)

Figure 4 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
著者:: James R. Larkin (14936324)
出版事項: (2025)

Figure 5 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
著者:: James R. Larkin (14936324)
出版事項: (2025)

Table 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
著者:: James R. Larkin (14936324)
出版事項: (2025)

Supplementary Table S4 from Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)
著者:: Chaoyang Zhang (15051876)
出版事項: (2025)

Supplementary Table S6 from Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)
著者:: Chaoyang Zhang (15051876)
出版事項: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
著者:: Iris van 't Erve (15054503)
出版事項: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
著者:: Kala Visvanathan (14952973)
出版事項: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
著者:: Kala Visvanathan (14952973)
出版事項: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
著者:: Kala Visvanathan (14952973)
出版事項: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
著者:: Kala Visvanathan (14952973)
出版事項: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
著者:: Kala Visvanathan (14952973)
出版事項: (2025)

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
著者:: Emil Christensen (15054394)
出版事項: (2025)

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
著者:: Emil Christensen (15054394)
出版事項: (2025)

Supplementary Data 2 from Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
著者:: Ismael Fernández-Miranda (15051932)
出版事項: (2025)

Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
著者:: Sofie H. Tolmeijer (15313251)
出版事項: (2025)

Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
著者:: Sofie H. Tolmeijer (15313251)
出版事項: (2025)

Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
著者:: Sofie H. Tolmeijer (15313251)
出版事項: (2025)

TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
著者:: Lavanya Sivapalan (15314248)
出版事項: (2025)

Integrating urinary metabolomics and clinical datasets for multi-cancer detection
著者:: Dongyong Lee (18786694)
出版事項: (2025)

Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
著者:: Andrew A. Davis (15030032)
出版事項: (2025)

Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
著者:: Morten Lapin (15056728)
出版事項: (2025)

Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
著者:: Morten Lapin (15056728)
出版事項: (2025)

Supplemental Table 3 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
著者:: Morten Lapin (15056728)
出版事項: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
著者:: Nam Q. Bui (14958210)
出版事項: (2025)

Data Sheet 3_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
著者:: Hailong Pang (12841991)
出版事項: (2025)

Data Sheet 2_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
著者:: Hailong Pang (12841991)
出版事項: (2025)

Data Sheet 1_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
著者:: Hailong Pang (12841991)
出版事項: (2025)

ROC curve analysis of a set of biomarkers obtained via untargeted metabolomics in serum samples from children infected with DENV compared to Control.
著者:: Ricardo E. Correa Fierro (22676430)
出版事項: (2025)

Workflow of untargeted metabolomics in serum samples from children infected with DENV.
著者:: Ricardo E. Correa Fierro (22676430)
出版事項: (2025)

Table 1_Cross-species validation of a 6-miRNA blood signature for Parkinson’s disease: from MPTP mice to human PBMC and serum exosomes.docx
著者:: Nagyum Jung (22686458)
出版事項: (2025)

Supplementary Table S3 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
著者:: Jun Wang (15051911)
出版事項: (2025)

PLS-DA regression model from untargeted metabolomics of serum samples from children infected with dengue and controls.
著者:: Ricardo E. Correa Fierro (22676430)
出版事項: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
著者:: Katleen Janssens (15053356)
出版事項: (2025)

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
著者:: Ankita Mitra (17141783)
出版事項: (2025)

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_hq1arrvr4vsdkck4tada9q372p